問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
Principal Investigator
李日翔
下載
2024-01-01 - 2030-12-31
Condition/Disease
Test Drug
Participate Sites17Sites
Recruiting17Sites
2018-12-07 - 2024-12-31
Participate Sites6Sites
Terminated6Sites
Division of Hematology & Oncology
2026-03-01 - 2035-01-31
Participate Sites4Sites
2018-05-01 - 2023-09-30
TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer
Keytruda injection
Participate Sites15Sites
Recruiting1Sites
Terminated13Sites
Division of Thoracic Medicine
2015-01-01 - 2018-12-31
stage IIIB/IV or recurrent, adenocarcinoma subtype non-small cell lung cancer
Nintedanib
全部
